News releases
Date
Language

Type of release


Download

Full announcement
Jun 08, 2012

Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for the ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes.

Further information:


  

Media: 		Investors:
Anne Margrethe Hauge Kasper Roseeuw Poulsen
Tel: (+45) 4442 3450 Tel: (+45) 4442 4303
amhg@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575
kiau@novonordisk.com jlis@novonordisk.com

Company Announcement No 37 / 2012